Loading company…
Senseera develops biomarker platforms for non-invasive diagnostics and personalized medicine.
Founded in 2020 and based in Jerusalem, Senseera develops platforms that analyze blood biomarkers for diagnostics and medicine research. Its cfChIP-seq technology profiles chromatin interactions and epigenetic modifications, while GEM BIOMARKERS™ targets liquid biopsy applications, particularly cancer detection. In January 2025, it raised USD 7.1 million in seed funding led by Lightspeed Venture Partners, with i-Next Ventures and Lowy Medical Research Institute participating. The funding will advance its liquid biopsy platform.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in